Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS seeks $1 billion balance sheet boost

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibbplans to strengthen its balance sheet with up to an additional $1 billion by 2011 from improvements in working capital. Chief financial officer Jean-Marc Huet said that the company would increase the speed of payments made to BMS from partners and vendors and would slow down payments going out from the firm. BMS also wants to improve commercial terms and the accuracy of its inventory audits. Currently, the company has around $7.2 billion in cash and expects to receive an additional $1 billion from the sale of its 16.6% stake in ImClone SystemstoLilly.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC032122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel